{"DataElement":{"publicId":"4902262","version":"1","preferredName":"Genetic Counseling Report BRCA1 Or BRCA2 Gene Mutation Or Gene Rearrangement Confirmation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding the confirmation of BRCA1 or BRCA2 mutation or BRCA rearrangements by genetic consultation reports.","longName":"BRCA_GN_MUT_REARR_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"4892434","version":"1","preferredName":"Genetic Counseling Report BRCA1 Or BRCA2 Gene Mutation Or Gene Rearrangement Confirmation Clinical Trial Eligibility Criteria","preferredDefinition":"A communication process between a specially trained health professional and a person concerned about the genetic risk of disease.  The person's family and personal medical history may be discussed, and counseling may lead to genetic testing._A short textual account; having provided a short account._Tumor suppressor genes located on human chromosome 17q12-21. The mutation of these genes is associated with the formation of familial breast and ovarian cancer._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._This gene is involved in cell cycle control, DNA repair and the maintenance of genomic stability. It also plays a role in the proliferation of embryonic cells._change occurring in one gene._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Any DNA sequence rearrangement that results in the creation of a novel protein-coding capacity. Within certain genes, gene rearrangement is a normal part of development, facilitating the affinity maturation of B and T lymphocytes as well as class switching of immunoglobulins._Having been established or verified._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"4892431v1.0:4892432v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"4892431","version":"1","preferredName":"Genetic Counseling Report","preferredDefinition":"A communication process between a specially trained health professional and a person concerned about the genetic risk of disease.  The person's family and personal medical history may be discussed, and counseling may lead to genetic testing.:A short textual account; having provided a short account.","longName":"C15240:C25375","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Genetic Counseling","conceptCode":"C15240","definition":"The process whereby an expert in hereditary disorders provides information about risk and clinical burden of a disorder or disorders to patients or relatives in families with genetic disorders as an aid to making informed and responsible decisions about marriage, children, early diagnosis, and handling disability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Report","conceptCode":"C25375","definition":"A short textual account; having provided a short account.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A65A4E3-F3BA-8C53-E050-BB89AD437175","latestVersionIndicator":"Yes","beginDate":"2015-07-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-08","modifiedBy":"ONEDATA","dateModified":"2015-07-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4892432","version":"1","preferredName":"BRCA1 Gene Or BRCA2 Gene Gene Mutation Or Gene Rearrangement Confirmation Clinical Trial Eligibility Criteria","preferredDefinition":"Tumor suppressor genes located on human chromosome 17q12-21. The mutation of these genes is associated with the formation of familial breast and ovarian cancer.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:This gene is involved in cell cycle control, DNA repair and the maintenance of genomic stability. It also plays a role in the proliferation of embryonic cells.:change occurring in one gene.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:Any DNA sequence rearrangement that results in the creation of a novel protein-coding capacity. Within certain genes, gene rearrangement is a normal part of development, facilitating the affinity maturation of B and T lymphocytes as well as class switching of immunoglobulins.:Having been established or verified.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"4892432v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BRCA1 Gene","conceptCode":"C17965","definition":"This gene plays a role in cell cycle control, regulation of transcription and the maintenance of genomic stability. It is also involved in the inhibition of mammary cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"BRCA2 Gene","conceptCode":"C18120","definition":"This gene is involved in cell cycle control, DNA repair and the maintenance of genomic stability. It also plays a role in the proliferation of embryonic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Gene Mutation","conceptCode":"C18093","definition":"The result of any gain, loss or alteration of the sequences comprising a gene, including all sequences transcribed into RNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Gene Rearrangement Process","conceptCode":"C16611","definition":"Any DNA sequence rearrangement that results in the creation of a novel protein-coding capacity. Within certain genes, gene rearrangement is a normal part of development, facilitating the affinity maturation of B and T lymphocytes as well as class switching of immunoglobulins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A65A4E3-F3D1-8C53-E050-BB89AD437175","latestVersionIndicator":"Yes","beginDate":"2015-07-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-08","modifiedBy":"ONEDATA","dateModified":"2015-07-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A65A4E3-F3E2-8C53-E050-BB89AD437175","latestVersionIndicator":"Yes","beginDate":"2015-07-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-08","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"9825_Theradex_07.08.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876422","version":"1","longName":"Disease Status & Genetics","context":"Theradex"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"If BRCA testing is done by or","type":"Preferred Question Text","description":"If BRCA testing is done by organization other than Myriad Laboratories, does the genetic consultation report from a qualified medical professional confirm that the laboratory results show a recognized germline deleterious BRCA1 or BRCA2 mutation or BRCA rearrangements?","url":null,"context":"Theradex"},{"name":"Theradex - If BRCA testing is done by organization other than Myriad Laboratories, is documentation from a qualified medical professional (e.g., ovarian cancer specialty physician involved in the field, high risk genetics physician, genetics counselor)","type":"Alternate Question Text","description":"If BRCA testing is done by organization other than Myriad Laboratories, is documentation from a qualified medical professional (e.g., ovarian cancer specialty physician involved in the field, high risk genetics physician, genetics counselor) listing the mutation and  deleterious BRCA1 or BRCA2 mutation or BRCA rearrangements is available?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF488FF-BC68-EF42-E050-BB89AD435DE4","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"HARTLEYG","dateModified":"2016-07-05","changeDescription":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}